Continued research and innovative technologies in the coming years are likely to assist in designing potent NQO1 futile substrates suitable for the treatment of different human cancers, NQO1-based reagents for drug delivery, guided cancer surgery, and combined theranostic compounds that deliver the drug payload and also allow tumor imaging. The gene discussed is NQO1; the disease is cancer.